Nobel Prize in Physiology or Medicine

Corner Therapeutics Announces First Publication on Proprietary Catalytic Adjuvant Platform

Retrieved on: 
星期三, 十一月 8, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Vaccine, DC, Antigen, MBio, Lipid, Cytokine, Infection, Virus, Protein, Observation, Pain scale, Corner, B cell, Lung, Vaccination, Immune system, COVID-19, Immunity, Medicine, Cancer, Messenger, Blood, Nobel Prize, Therapy, Nobel Prize in Physiology or Medicine, Patient, Doctor of Philosophy, Physiology, LNP

Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.

Key Points: 
  • Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.
  • The enhanced T cell immunogenicity of Corner Therapeutics’ Catalytic Adjuvant platform was also observed for antibody production.
  • “This publication is an exciting milestone for Corner Therapeutics, offering the first overview of our catalytic adjuvants as tools to stimulate unprecedented vaccine immunogenicity,” said Jonathan Kagan, Ph.D., Scientific Co-founder and Advisor at Corner Therapeutics and lead author of the publication.
  • “As we continue to develop our Catalytic Adjuvant platform, we look forward to exploring its broad potential to generate lifelong immunity for patients young and old.”

American Liver Foundation Hosts the 32nd Annual Irwin M. Arias Symposium

Retrieved on: 
星期四, 十一月 2, 2023
Massachusetts General Hospital, Science, ALF, MACP, MIT, ISCB Senior Scientist Award, National Institutes of Health, Gastroenterology, Physician, Danny Howells, American Liver Foundation, Liver, MD, Doctor of Philosophy, Liver disease, Research, Engineering, Disease, Biology, Biomedical engineering, NIH, Nobel Prize, Hepatology, Collection, Nobel Prize in Physiology or Medicine, Patient, Diagnosis, Hospital, Bangladesh Technical Education Board, Wolfram Goessling, Pharmaceutical industry, Nursing, Physiology, Medicine

FAIRFIELD, N.J., Nov. 2, 2023 /PRNewswire/ -- The American Liver Foundation is pleased to host its 32nd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on November 16th from 9AM to 5PM ET. This one-day virtual and in-person program brings together hundreds of leading biomedical scientists and physicians from across the globe and is designed to bridge the remarkable advances in basic biology and engineering with the understanding of liver diseases and their treatment.

Key Points: 
  • Virtual and in-person event, Bridging Basic Science and Liver Disease, brings together hundreds of leading biomedical scientists and physicians from across the globe
    FAIRFIELD, N.J., Nov. 2, 2023 /PRNewswire/ -- The American Liver Foundation is pleased to host its 32nd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease , on November 16th from 9AM to 5PM ET.
  • ALF hosts Arias Symposium, Bridging Basic Science and Liver Disease, Nov. 16th 9AM-5PM ET.
  • alfevents.org/ariassymposium
    "ALF's annual Arias Symposium has become a go-to event for scientists interested in exploring the connections between research conducted in the lab and treatments delivered in the clinic," said Lorraine Stiehl, CEO, American Liver Foundation.
  • "ALF's Arias Symposium has been a model in addressing this challenge with respect to the liver.

COVID proved the therapeutic potential of RNA technology – making it more available is the next goal

Retrieved on: 
星期四, 十月 26, 2023
Nobel Prize in Physiology or Medicine, Translation, Technology, Health, Vaccine, Physiology, RNA, Genetic code, Research, Cell, Protein, Nature, Particle size, Immune system, Medicine, University, School, Messenger, Infection, Safety, Cancer, Toxicity, Nobel Prize, DNA, Pharmaceutical industry, Phosphorus, Environmental remediation, COVID

Detailed methodology to deliver RNA vaccines to cells was also not easily available to the research community.

Key Points: 
  • Detailed methodology to deliver RNA vaccines to cells was also not easily available to the research community.
  • For these reasons we have published a protocol detailing how to make and package RNA with commercially available reagents.

How RNA therapies work

  • The concept behind RNA therapies is elegant and simple, in theory.
  • There are two distinct components: the RNA payload and the fatty envelope, made of lipid nanoparticles, which safely delivers the payload to cells.
  • Read more:
    Messenger RNA: how it works in nature and in making vaccines

    It is hard to believe now, but even in the early 2000s RNA therapies were widely considered to be a pipe dream.

Delivering the message

  • RNA is a negatively charged, unstable molecule and cannot maintain its structure in the body without some sort of protective casing.
  • It was only in the 2010s that lipid nanoparticles were developed and identified as a potential mechanism for delivery.
  • Then, before injection into the body, this assemblage is converted to a neutral pH, reducing potential toxicity in the body.

Time in the spotlight

  • By the time the COVID pandemic arrived, the essential components to make a viable RNA vaccine had emerged.
  • RNA vaccines were especially appealing as they can be rapidly synthesised in the lab using just the genetic code of the virus.
  • The result has been that labs around the world are developing their own techniques from scratch, leading to a grossly inefficient system.

The democratisation of RNA technology

  • It is a standardised technique researchers can use as a baseline for RNA therapies without the need for proprietary products.
  • This will mean more people around the world will be able to bring RNA technology into the clinic, broadening its scope, impact and safety.
  • We have only seen the tip of the iceberg in terms of the therapeutic potential of RNA technology.


This work was supported by funding from New Zealand Ministry of Business Innovation and Employment (RTVU1603 and Vac 19008), Research Trust of Victoria University of Wellington (project number 400662) and The Hugh Green Foundation.

EnginZyme Produces Key mRNA Vaccine Ingredient Using Biocatalysis

Retrieved on: 
星期三, 十月 25, 2023
Chemicals, Plastics, Retail, Manufacturing, Technology, Pharmaceutical, Supply Chain Management, Infectious Diseases, Artificial Intelligence, Transport, Science, Biotechnology, Logistics, Health, Research, Medical Supplies, Physiology, Uridine, FDA, CGMP, Pfizer–BioNTech COVID-19 vaccine, Therapy, Vaccine, RNA, CDMO, Enzyme, R, Ajinomoto, Hoarding, COVID-19, World Health Organization, Medicine, Messenger, Nobel Prize in Physiology or Medicine, Nobel Prize, Pseudouridine, Fine chemical, Pharmaceutical industry

The companies said they had already synthesized enough pseudouridine for more than half a billion doses of vaccine in a facility that is fully cGMP* compliant.

Key Points: 
  • The companies said they had already synthesized enough pseudouridine for more than half a billion doses of vaccine in a facility that is fully cGMP* compliant.
  • The enzymatic process EnginZyme has perfected is cleaner and more efficient than the chemical synthesis methods currently used.
  • A critical impurity, alpha-pseudouridine, which is a by-product of the chemical synthesis of beta-pseudouridine, is eliminated in EnginZyme's patented enzymatic synthesis.
  • This project with EnginZyme has been particularly rewarding because of its potential to improve the global supply chain for vaccine ingredients.”
    N1-methylpseudouridine-5’-triphosphate, which is derived from pseudouridine, helps stabilize and reduce the immunogenicity of mRNA.

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

Retrieved on: 
星期一, 十月 2, 2023
Vaccine, Nobel Prize, COVID-19, Messenger, COVID-19 vaccine, Health, Nobel Prize in Physiology or Medicine, Pharmaceutical industry, Physiology, Medicine

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, would like to congratulate Drew Weissman, M.D., Ph.D., a member of the Company’s Scientific Advisory Board, for receiving the Nobel Prize in Physiology or Medicine, based on his pioneering work enabling the development of mRNA COVID-19 vaccines.

Key Points: 
  • FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, would like to congratulate Drew Weissman, M.D., Ph.D., a member of the Company’s Scientific Advisory Board, for receiving the Nobel Prize in Physiology or Medicine, based on his pioneering work enabling the development of mRNA COVID-19 vaccines.
  • “On behalf of our Board of Directors and all of our employees, I would like to congratulate Dr. Weissman for this extraordinary achievement,” said Harlan Weisman, M.D., Chief Executive Officer and Vice Chairman of TFF Pharmaceuticals.
  • “These discoveries laid the groundwork for the rapid development of mRNA-based COVID-19 vaccines, which proved to have an enormous impact on human health during the global pandemic.”

Capstan Therapeutics Co-Founder Drew Weissman, M.D., Ph.D., Awarded Nobel Prize in Physiology or Medicine for Enabling Rapid Development of RNA-based COVID-19 Vaccine

Retrieved on: 
星期一, 十月 2, 2023
Health, Genetics, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Nobel Prize, Partnership, University, Infection, Capstan equation, Cell, Messenger, Neurosurgery, ARD International Music Competition, Nobel Prize in Physiology or Medicine, Therapy, Medicine, Disease, Pharmaceutical industry, Vaccine, Capstan, Physiology

Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Key Points: 
  • Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
  • Dr. Weissman shares the award with his research collaborator of many years, Katalin Karikó, Ph.D., an adjunct professor of neurosurgery at the University of Pennsylvania.
  • “It has been a privilege to work with Dr. Weissman and our other collaborators on the founding technology for Capstan which was made possible by his many years of work on mRNA biology and delivery leading up to the Nobel Prize,” said Dr. Haig Aghajanian, Capstan Co-Founder and Vice President of Research.
  • “It’s been so rewarding to work side-by-side with him.”
    “All of the Capstaneers congratulate Dr. Weissman and Dr. Karikó on receiving the 2023 Nobel Prize in Physiology or Medicine for their visionary research in unlocking the power of mRNA-based therapeutics,” said Dr. Laura Shawver, President and Chief Executive Officer of Capstan.

Lily Jan and Eve Marder to receive 2023 Pearl Meister Greengard Prize

Retrieved on: 
星期五, 九月 15, 2023
Nobel Prize, Neuron, National academy, Vincent Astor, Jack, Society, The arts, University, Partnership, BRAIN Initiative, Stanford Institutes of Medicine Summer Research Program, Rockefeller University, Academia Sinica, Howard Hughes Medical Institute, Woman, American Academy, Brandeis University, Brain, Metropolitan Museum of Art, Homeostasis, Potassium, Natural history, Museum, American Museum, Entomology, Neuroscience, Biophysics, Nobel Prize in Physiology or Medicine, Pearl Meister Greengard Prize, Metropolitan, Behavior, Peptide, Pharmaceutical industry, Medicine, Art, Science, Physiology

NEW YORK, Sept. 15, 2023 /PRNewswire/ -- Groundbreaking neuroscientists Lily Jan and Eve Marder will jointly receive the 2023 Pearl Meister Greengard Prize, an award which recognizes outstanding women scientists.

Key Points: 
  • NEW YORK, Sept. 15, 2023 /PRNewswire/ -- Groundbreaking neuroscientists Lily Jan and Eve Marder will jointly receive the 2023 Pearl Meister Greengard Prize, an award which recognizes outstanding women scientists.
  • "This year's awardees are two outstanding scientists who have made fundamental contributions to neurobiology," says Michael W. Young , Richard and Jeanne Fisher Professor, Nobel Laureate, and chair of the Pearl Meister Greengard Prize selection committee.
  • Marder, most recognized for her work understanding the modulation of neural networks, is the Victor and Gwendolyn Beinfield University Professor at Brandeis University.
  • To attend the Pearl Meister Greengard Prize ceremony and learn more about the award, register here .

Seeing what the naked eye can't − 4 essential reads on how scientists bring the microscopic world into plain sight

Retrieved on: 
星期二, 八月 22, 2023
Electron, Nobel Prize, DNA, Technology, Neuron, Music, Protein, Life, Poetry, Linsley, Classification, Anatomy, Neurodegenerative disease, Printing, 3D, Eye, Microscopy, Lens, Data collection, Intelligence, Brain, Research, Cell, Dicarboxylic acid, Nobel Prize in Physiology or Medicine, Science, Literacy, Oxytocin, Plant, Google Maps, Neuroscience, Student, Animal, Museum, Map, Sound, Cell division, AI, BioArt, Death, Environment, Microscope, Medical imaging, Vaccine, Computer data storage, Camera, Book

The microscope is an iconic symbol of the life sciences – and for good reason.

Key Points: 
  • The microscope is an iconic symbol of the life sciences – and for good reason.
  • For the life sciences, where understanding the function of a living thing often requires interpreting its form, imaging is vital to confirming theories and revealing what is yet unknown.

1. Seeing as identifying

    • But there is still a resolution gap between the smallest and largest structures of the cell.
    • Biophysicist Jeremy Berg drew an analogy to Google Maps: Though scientists could see the city as a whole and individual houses, they couldn’t make out the neighborhoods.
    • “I anticipate seeing new theories on how we understand cells, moving from disorganized bags of molecules to intricately organized and dynamic systems,” writes Berg.
    • Read more:
      Visualizing the inside of cells at previously impossible resolutions provides vivid insights into how they work

2. Seeing as scoping

    • After discerning individual components, scientists are tasked with charting how they interact with each other in the macrosystem of the body.
    • Researchers have been charting the brain by stitching together multiple snapshots like a photo mosaic.
    • They use different techniques to label a specific cell type and then image the whole brain at high resolution.
    • Likewise, knowing where every cell is located relative to each other doesn’t necessarily tell researchers how they function or interact.

3. Seeing as recognizing

    • Automated microscopes, for example, have made it possible to take time-lapse images of cells, resulting in massive amounts of data that require manual sifting.
    • Neuroscientist Jeremy Linsley and his team encountered this dilemma in their own work on neurodegenerative disease.
    • Read more:
      New AI technique identifies dead cells under the microscope 100 times faster than people can – potentially accelerating research on neurodegenerative diseases like Alzheimer's

4. Seeing as appreciating

UCSD John B. West Distinguished Lecture Series, Sponsored by MediPines, to Feature Nobel Laureate Dr. Gregg L. Semenza

Retrieved on: 
星期三, 八月 2, 2023
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, University, Health, Science, Education, Other Science, Nobel Prize, Critical care, Plaque, Q&A, Emeritus, Lecture, Section, UCSD, Doctor of Philosophy, Gas, Doctor of Science, Pacific Time Zone, Professor, Genetic distance, Johns Hopkins University, Division, Chandos Chair of Medicine and Anatomy, Nobel, Nobel Prize in Physiology or Medicine, Pharmaceutical industry, Nursing, Medical device, MD, Medicine, Physiology

West Distinguished Lecture event featuring Nobel Laureate Gregg L. Semenza, MD, PhD.

Key Points: 
  • West Distinguished Lecture event featuring Nobel Laureate Gregg L. Semenza, MD, PhD.
  • The lecture, titled “Hypoxia-Inducible Factors in Physiology and Medicine,” will take place on August 7, 2023 at noon Pacific Time via livestream from UCSD.
  • After introductory notes by Zea Borok, MD (Chair of Medicine, UCSD); Jess Mandel, MD, (Chief of Pulmonary, Critical Care and Sleep Medicine, UCSD); John B.
  • West, MD, PhD, DSc (Emeritus Professor of Medicine and Physiology at UCSD); and Steve Lee (CEO of MediPines), Dr. Semenza will deliver his lecture.

ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer

Retrieved on: 
星期二, 六月 20, 2023
Max Planck Institute for Medical Research, Nobel Prize, Partnership, Bristol Myers Squibb, RNA, AAV, Doctor of Philosophy, Harvard Medical School, Nobel Prize in Physiology or Medicine, Juno Therapeutics, Entrepreneurship, Kazan National Research Technological University, AI, Max Planck, R, Therapy, Pharmaceutical industry, Medicine, Physiology

SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).

Key Points: 
  • SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).
  • Throughout his career, Dr. Briggs has been leading teams to develop disruptive technological innovations in life sciences.
  • AbVitro was acquired by Juno Therapeutics, and shortly after by Bristol Myers Squibb, where Dr. Briggs led technology-focused teams.
  • “Adrian’s leadership and success in using technology to solve intractable problems ensure we remain at the forefront of technological advancements as we guide our promising therapies one step closer to the clinic,” said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX.